FDA OKs Roche triplet therapy for certain type of melanoma

July 31, 2020

Under Priority Review status, the FDA approves Roche’s (OTCQX:RHHBY) triplet therapy of Tecentriq (atezolizumab), Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma.

This is an example of the “cocktail” approach to treating cancer with drugs with different mechanisms of action. Atezolizumab is a PD-L1 blocker and cobimetinib and vemurafenib are kinase inhibitors.

https://seekingalpha.com/news/3598270-fda-oks-roche-triplet-therapy-for-certain-type-of-melanoma